Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized Controlled Clinical Study on the Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in the Treatment of Malignant Pleural and Peritoneal Effusion

NCT05565014 is registered in ClinicalTrials.gov with Sheng Hu as lead sponsor.

NCT NCT05565014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05565014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized Controlled Clinical Study on the Safety and Efficacy of Virus Activated Killer Immune Cells (VAK) in the Treatment of Malignant Pleural and Peritoneal Effusion
Lead sponsor
Sheng Hu
Phase
Phase 1
Overall status
Unknown status
Start date
July 24, 2020
Completion date
June 30, 2024
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant peritoneal effusion, malignant pleural effusion